meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic, hormone-sensitive prostate cancer
11
renal cell cancer (RCC)
endocrine therapy
androgen deprivation therapy (ADT)
abiraterone plus ADT
abiraterone plus docetaxel plus ADT
apalutamide plus ADT
darolutamide plus doxetaxel plus ADT
docetaxel plus ADT
enzalutamide
enzalutamide plus ADT
versus all
vs endocrine therapy
vs androgen deprivation therapy (ADT)
vs docetaxel plus ADT
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
graph
EGM
comparisons
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
docetaxel plus ADT
title
enzalutamide plus ADT
title
abiraterone plus ADT
title
abiraterone plus docetaxel plus ADT
title
darolutamide plus doxetaxel plus ADT
title
apalutamide plus ADT
title
androgen deprivation therapy (ADT)
title
STAMPEDE abiraterone, 2017 NCT00268476 metastatic, hormone-sensitive prostate cancer -9/-9
LATITUDE, 2019 NCT01715285 metastatic, hormone-sensitive prostate cancer -9/-9
PEACE-1, 2022 NCT01957436 metastatic, hormone-sensitive prostate cancer 355/355
TITAN, 2019 NCT02489318 metastatic, hormone-sensitive prostate cancer 525/527
ARASENS , 2022 NCT02799602 metastatic, hormone-sensitive prostate cancer 651/655
STAMPEDE docetaxel, 2016 NCT00268476 metastatic, hormone-sensitive prostate cancer -9/-9
NCI E3805 (Scott), 2017 NCT00309985 metastatic, hormone-sensitive prostate cancer 397/393
CHAARTED, 0 NCT00268476 metastatic, hormone-sensitive prostate cancer -9/-9
GETUG-AFU 15, 2013 NCT00104715 metastatic, hormone-sensitive prostate cancer -9/-9
ENZAMET, 2019 NCT02446405 metastatic, hormone-sensitive prostate cancer -9/-9
ARCHES, 2022 NCT02677896 metastatic, hormone-sensitive prostate cancer 574/576
Pathology:
metastatic, hormone-sensitive prostate cancer;
metastatic, hormone-sensitive prostate cancer
STAMPEDE abiraterone, 2017
LATITUDE, 2019
PEACE-1, 2022
TITAN, 2019
ARASENS , 2022
STAMPEDE docetaxel, 2016
NCI E3805 (Scott), 2017
CHAARTED, 0
GETUG-AFU 15, 2013
ENZAMET, 2019
ARCHES, 2022
docetaxel plus ADT
4
T0
T0
T1
T1
T1
T1
enzalutamide plus ADT
2
T1
T1
abiraterone plus ADT
2
T1
T1
abiraterone plus docetaxel plus ADT
1
T1
darolutamide plus doxetaxel plus ADT
1
T1
apalutamide plus ADT
1
T1
androgen deprivation therapy (ADT)
0
T0
T0
T0
T0
T0
T0
T0
T0
T0